--- title: "340B Risk Management" url: https://virtue340b.com/risk-management/ date: 2026-06-24 modified: 2026-08-06 lang: en author: "Toto SEO" description: "340B Risk ManagementSurface the 340B Program Risk CFOs Don't See Coming Covered entities carry ongoing financial, operational, and governance risk that never announces itself through an audit notice. Virtue 340B..." word_count: 2356 --- # 340B Risk Management # 340B Risk ManagementSurface the 340B Program Risk CFOs Don't See Coming Covered entities carry ongoing financial, operational, and governance risk that never announces itself through an audit notice. Virtue 340B delivers independent, CIA-led compliance audits and continuing monitoring services that surface and quantify that exposure - protecting the health services your program supports - before it becomes costly to unwind. [ Learn More About Our Independent Audits ](https://virtue340b.com/risk-management/independent-340b-audits/) [ Learn About Our 340B Continuous Monitoring Service ](https://virtue340b.com/risk-management/340b-continuous-monitoring-program/) ## Compliance Gaps Create Consequences Far Beyond a Regulatory Finding For a 340B hospital or health system, the impact reaches well past the pharmacy department, complicating reimbursement, budgeting, and forecasting. The question is not whether the program is running, but whether the organization can defend it if challenged. ### Regulatory & Financial Exposure - HRSA audit findings and formal deficiencies - Mandatory manufacturer repayment obligations - Corrective action plans under HRSA oversight - Compressed, high-pressure remediation timelines ### Organizational & Strategic Impact - Eroded board and auditor confidence in reported savings - Distorted budgets, forecasting, and reimbursement - Inability to demonstrate that reasonable oversight was in place - Reputational risk extending beyond the pharmacy department [ Request an Independent Audit ](https://virtue340b.com/book-a-consult/) ## Compliance on Paper Is Not the Same as Low Risk Compliance A program can pass a point-in-time review while still carrying significant underlying risk. Technical compliance at a single moment does not confirm that controls are functioning, that monitoring is active, or that operational workflows match documented policy. Genuine risk reduction requires effective controls that preserve the 340B discount, consistent monitoring, and governance that identifies operational drift before it becomes a program integrity issue. When policies do not reflect actual operations, those documents cannot substantiate compliance with 340B program requirements during an audit. ![compliance-risk-management-virtue-340b](https://virtue340b.com/wp-content/uploads/2026/06/compliance-risk-management-virtue-340b.jpg) ## The Risk Domains We Evaluate in Every 340B Audit Compliance risk in the 340B program - established under Section 340B of the Public Health Service Act - does not concentrate in a single area. It accumulates across interconnected domains, from the procurement of discounted drugs to governance documentation, and weakness in one can accelerate exposure in others. We evaluate all six during every Independent 340B Compliance Audit. - ### Provider Eligibility Management Errors in how provider eligibility is determined, documented, and maintained in split-billing systems are among the most common sources of meaningful audit findings. Status changes not communicated to the TPA create eligibility mismatches at the transaction level. - ### Patient Eligibility Determinations Ineligible patients passing through the data feed, particularly via referral claims or new encounter types, are a frequent HRSA target. Encounter or location code additions in the EHR can silently introduce ineligible claims downstream.- ### Contract Pharmacy Oversight The risk of ineligible claims captured at contract, specialty, or retail pharmacies is structurally higher than at in-house dispensing sites. Without active monitoring, undetected exposure accumulates over time.- ### Data Integrity & System Configuration Virtual inventory mismanagement occurs when split-billing logic no longer separates 340B and non-340B utilization. In one case, a TPA failed to ingest one month of data, defaulting all purchases to the non-340B account at full price.- ### Governance & Documentation Maturity Informal workflows, undocumented decisions, and insufficient internal controls are difficult to remediate and are often the root cause behind multiple transaction-level findings.- ### Policies That No Longer Reflect Operations Outdated SOPs that exist in documentation but do not match actual workflows cannot substantiate compliance with 340B program requirements when an auditor requests evidence. ## Conditions That Warrant a 340B Compliance Review These conditions tend to show up before compliance findings do. On their own they don't prove anything went wrong, but they're worth a closer look. **Act Now - Immediate Assessment** **Monitor Closely - Accumulating Risk** ## Beyond a Compliance Checklist - A Governance-Grade Audit Methodology Our audits are led by [Edward Vargas, a Certified Internal Auditor (CIA)](https://virtue340b.com/about-us/team/#edward) - a credential rooted in governance, risk methodology, and control effectiveness. That framework is structurally different from pharmacy-led or legal-led reviews. **Pharmacy-led review** Evaluates whether technical compliance requirements are met. **Legal-led review** Emphasizes regulatory interpretation and statutory exposure. **CIA methodology** Adds root-cause analysis, control-effectiveness assessment, accountability structures, and sustainable 340B management practices. In practice, findings are organized by risk level, exposure, and control maturity - not a flat list of deficiencies. Each one names the underlying cause, recommended corrective actions, responsible stakeholders, implementation priorities, and suggested monitoring activities. **A CIA-led audit confirms not just that the rules are met, but that your controls actually** [ Schedule Your Consultation ](https://virtue340b.com/book-a-consult/) Led by Edward Vargas, CIA · [Author of 340B Mastery](https://virtue340b.com/content-hub/340b-mastery-book/) ## Why Vendor Independence Matters in a Risk Review When the organization reviewing your compliance has a financial relationship with the TPA, software platform, or contract pharmacy network being evaluated, it faces an inherent challenge in providing fully objective oversight - the review may focus on operational improvements rather than whether the program's underlying assumptions, controls, and configurations remain appropriate. For a CFO or COO, the question is not whether a vendor-affiliated reviewer is trustworthy - it is whether the organization has a source of risk assessment free from competing business interests. Independence is a structural characteristic of our business, not a preference. **As an Independent Firm, Virtue 340B:** ### Conflict-of-Interest Documentation for Procurement When your procurement or vendor-evaluation process requires formal conflict-of-interest disclosures, we provide documentation confirming that Virtue 340B does not sell 340B software, operate 340B programs, administer split-billing systems, receive vendor incentives, or maintain any financial arrangement that could influence audit conclusions. Our role is not to replace your internal teams or existing vendors - it is to provide an independent layer of oversight that helps leadership understand risk exposure and validate program assumptions. ## Where Compliance Risk Actually Comes From Many of the most significant exposures we identify result not from misconduct, but from operational drift that accumulates quietly over months or years. In nearly every case, proactively addressing that drift costs far less than the repayment obligations, corrective actions, and leadership scrutiny that follow if it is left unaddressed. ### A Case Study in Closing the Compliance Gap A covered entity maintained well-documented provider eligibility records and a sound determination process. On the surface, both the policies and the roster appeared correct. A closer review of the data flow revealed that provider status changes were not consistently communicated to the split-billing system. Determinations correct on paper were not reflected in the system responsible for claim qualification The gap was addressed through a structured remediation plan and a [monitoring procedure](https://virtue340b.com/risk-management/340b-continuous-monitoring-program/) - identified before it evolved into a formal HRSA finding. Because we work across covered-entity operations, compliance auditing, and vendor environments, the control gap was caught before it became a formal HRSA finding [ Request An Independent Audit or Continuous Monitoring Service ](https://virtue340b.com/book-a-consult/) ![virtue-risk-management](https://virtue340b.com/wp-content/uploads/2026/06/virtue-risk-management.jpg) ## 340B Compliance Audit and Monitoring Services Virtue 340B offers two engagement structures. The right level depends on your objectives, known risk factors, recent audit history, and current confidence in program integrity. ### Independent Compliance Audit - Patient and provider eligibility determinations - Purchasing, replenishment, and inventory controls - Contract pharmacy arrangements and oversight - Policies, governance, and documentation maturity - Findings organized by risk level and control maturity ### Continuous Monitoring Services - 100% of claims and purchases reviewed quarterly, findings inside the 90-120 day adjustment window. - Quarterly purchase-to-claims matching catches anomalies and builds an audit trail. - Contract pharmacies checked for duplicate discounts and diversion, limiting 340B pricing to eligible patients. - Quarterly executive presentations, plus an annual mock HRSA audit For full scope details, timelines, and deliverables, visit the [Independent 340B Compliance Audit](https://virtue340b.com/risk-management/independent-340b-audits/). [ Schedule Your Risk Assessment ](https://virtue340b.com/book-a-consult/) ## When to Engage an Independent Reviewer An independent audit should occur at least every 12-24 months for most covered entities. Programs in complex, vendor-managed environments benefit from more frequent oversight. Certain events should prompt a review regardless of cycle: ## What We Need to Begin a Risk Review Most organizations already have what is needed - no extensive preparation required before an initial consultation. These materials let us evaluate not only transaction-level compliance, but the effectiveness of your oversight structure, monitoring processes, and internal controls. ## Why Governance Findings Take the Longest to Fix Transaction-level errors can often be corrected once identified. Governance and process findings require cross-functional coordination - which is exactly what our remediation roadmaps are built to coordinate across. Issues like eligibility workflows that rely on informal communication, oversight concentrated in a single individual, or unmonitored contract pharmacy arrangements typically demand coordination across pharmacy, compliance, finance, credentialing, IT, and leadership. Our roadmaps assign accountability and sequence the work to: [ Schedule Your Consultation ](https://virtue340b.com/book-a-consult/) ### Independent 340B Compliance Audits A comprehensive, CIA-led review of your program's eligibility, pharmacy controls, governance, and documentation. [ Lear About Our Independent 340b Audits ](https://virtue340b.com/risk-management/independent-340b-audits/) ### Continuous 340B Program Monitoring Quarterly rotating reviews that maintain ongoing compliance visibility between point-in-time audits. [ Lear About Our Continuous Monitoring Program ](https://virtue340b.com/risk-management/340b-continuous-monitoring-program/) ## Frequently Asked Questions ### Who is eligible to participate in the 340B program? Eligible 340B providers are defined under the 340B statute and include federally qualified health centers, disproportionate share hospitals, critical access hospitals, Ryan White grantees, state AIDS drug assistance programs, and other safety net organizations. The program enables covered entities to stretch scarce funding by purchasing drugs at discounted prices, with savings reinvested into patient care. Each entity type has distinct eligibility documentation requirements administered by HRSA, and maintaining current proof of eligibility throughout participation is a core compliance obligation. ### How is the 340B price calculated, and who enforces it? The 340B ceiling price is calculated based on the average manufacturer price minus a unit rebate amount, and manufacturers are legally required to sell outpatient drugs at discounted prices to covered entities. HRSA administers and monitors program compliance, while manufacturers are obligated to provide drugs at reduced prices as a condition of Medicaid participation. Disputes over ceiling price calculations have increased as drug companies seek to restrict contract pharmacy access, making pricing documentation an active audit risk area. ### What is the 340B prime vendor program, and does it affect compliance? The prime vendor program, administered by Apexus under HRSA contract, helps covered entities access drugs at or below the ceiling price through centralized purchasing. Participation is voluntary but provides meaningful cost advantages, particularly for smaller entities. While the program itself is not a compliance risk area, the purchasing data it generates must be accurately reconciled against dispensation records during an audit to avoid diversion or duplicate discount findings. ### How are covered entities expected to use 340B savings? The program does not prescribe a specific use of savings, but its intent is to help covered entities expand patient care and services for vulnerable populations. When organizations reinvest savings into services beyond pharmacy, documenting that reinvestment supports program integrity and demonstrates alignment with the program's public health mission. Entities that cannot clearly account for how they use 340B resources may face heightened scrutiny during HRSA reviews focused on program intent. ### What do audits conducted by HRSA typically examine? HRSA audits evaluate whether covered entities meet core requirements, including patient eligibility determinations, provider eligibility documentation, duplicate discount controls, and diversion prevention. They also examine whether drugs were dispensed only to eligible patients, whether policies and procedures reflect actual operations, and whether split-billing systems are correctly configured and maintained. Entities are typically given limited time to produce documentation once selected, which is why audit-ready records must be maintained continuously. ### How do pharmacy benefit managers affect 340B compliance risk? PBMs affect compliance primarily through their role in processing claims at contract pharmacies, where the interaction between pharmacy benefit systems and 340B accumulation logic creates data integrity risk. When a PBM's claim adjudication does not correctly identify 340B-eligible transactions, entities may fail to capture eligible claims or generate duplicate discounts on Medicaid-reimbursed prescriptions. Entities should confirm that TPA and PBM configurations are aligned and that claim separation functions accurately at the transaction level. ### What is the compliance difference between 340B and non-340B hospitals in the same system? The obligations differ fundamentally: 340B hospitals operate under mandatory requirements for patient eligibility, duplicate discount avoidance, and purchasing controls that do not apply to non-participating facilities. When health systems manage both under shared infrastructure, the separation of purchasing, dispensation, and billing becomes a critical control area, as errors can result in diversion findings or repayment obligations. Mixed environments require clearly documented workflows and verified system configurations across all dispensing locations. ### Can covered entities dispense 340B drugs through retail or specialty pharmacies? Yes, through contract pharmacy arrangements, but this introduces additional requirements around patient eligibility verification, claim capture accuracy, and data integrity. Drug companies have increasingly restricted the number of contract pharmacy locations through which they will sell discounted drugs, creating a more complex environment. Entities should ensure all contract pharmacy arrangements are documented, actively monitored, and updated to reflect current manufacturer restrictions to avoid claim capture failures or repayment exposure. ### What should AIDS drug assistance programs know about 340B compliance? ADAPs, including state programs and Ryan White grantees, are among the covered entity types eligible to access discounted drugs for their patient populations. These programs often serve patients with complex medication needs, requiring careful eligibility documentation and coordination across dispensing sites. Because their patient populations and funding structures differ from hospital-based entities, ADAP participants should ensure their compliance frameworks are reviewed independently and not modeled directly on hospital-based audit standards. ![Eddie-founder-headshot](https://virtue340b.com/wp-content/uploads/2025/08/Eddie-founder-headshot-scaled.jpg) "The control gap was identified before it evolved into a formal HRSA finding. That is the difference between proactive risk management and reactive damage control." **Edward Vargas, CIA · Founder, Virtue 340B** ## Specialized 340B Risk Review for Complex Operations - ### Health Systems & Large Hospitals Multi-site complexity across diverse clinical environments with varying oversight. We standardize 340B compliance and surface risk enterprise -wide.**[How We Help Health Systems](https://virtue340b.com/covered-entities/health-systems-and-large-hospitals/)** - ### Rural Hospitals Focused review addresses the unique constraints of smaller facilities while protecting 340B program benefits and ensuring audit readiness.**[How We Help Rural Hospitals](https://virtue340b.com/covered-entities/rural-hospitals/)**- ### FQHCs & Grantees Specialized attention to federally qualified health center requirements strengthens program integrity for underserved populations.**[How We Help FQHCs & Grantees ›](https://virtue340b.com/covered-entities/federally-qualified-health-centers-and-grantees/)** ## Reduce exposure. Strengthen oversight. Defend your program. We work with covered entities across all 50 states and Puerto Rico - from disproportionate share and rural hospitals to FQHCs and other grantees - to identify compliance risk before it compromises drug cost savings or triggers regulatory liability. ### Schedule a Consultation Not sure which engagement fits? A consultation clarifies your current risk profile and the right scope - no commitment required. [ Schedule Your Consultation ](https://virtue340b.com/book-a-consult/) ### Enroll in Continuous Monitoring Quarterly rotating reviews that maintain ongoing visibility into compliance posture across all pharmacy service areas - flagging emerging risk between point-in-time audits. [ Learn About Continous Monitoring ](https://virtue340b.com/risk-management/340b-continuous-monitoring-program/)